ATE218556T1
(de)
|
1995-11-17 |
2002-06-15 |
Biotechnolog Forschung Gmbh |
Epothilon-derivate und deren herstellung
|
AU753546B2
(en)
|
1996-11-18 |
2002-10-24 |
Helmholtz-Zentrum Fuer Infektionsforschung Gmbh |
Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
|
WO1999001124A1
(en)
|
1996-12-03 |
1999-01-14 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US6867305B2
(en)
*
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6660758B1
(en)
*
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
US6605599B1
(en)
*
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
US6365749B1
(en)
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
FR2775187B1
(fr)
*
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
US6380395B1
(en)
|
1998-04-21 |
2002-04-30 |
Bristol-Myers Squibb Company |
12, 13-cyclopropane epothilone derivatives
|
US6498257B1
(en)
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
DE19820599A1
(de)
*
|
1998-05-08 |
1999-11-11 |
Biotechnolog Forschung Gmbh |
Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
|
DE19826988A1
(de)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
JP4662635B2
(ja)
|
1998-11-20 |
2011-03-30 |
コーサン バイオサイエンシーズ, インコーポレイテッド |
エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料
|
CZ301498B6
(cs)
*
|
1999-02-22 |
2010-03-24 |
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) |
C-21 modifikované epothilony
|
US20020058286A1
(en)
*
|
1999-02-24 |
2002-05-16 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
EP3222619A1
(en)
|
1999-04-15 |
2017-09-27 |
Bristol-Myers Squibb Holdings Ireland |
Cyclic protein tyrosine kinase inhibitors
|
WO2001038317A2
(en)
*
|
1999-11-24 |
2001-05-31 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
Fungicidal melithiazole derivatives
|
US6518421B1
(en)
*
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
US20020045609A1
(en)
*
|
2000-05-26 |
2002-04-18 |
Gary Ashley |
Epothilone derivatives and methods for making and using the same
|
CA2422500A1
(en)
*
|
2000-09-22 |
2003-03-18 |
Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) |
Triazolo-epothilones
|
IL155306A0
(en)
*
|
2000-10-13 |
2003-11-23 |
Univ Mississippi |
Methods for producing epothilone derivatives and analogs and epothilone derivatives and analogs produced thereby
|
CN1489466A
(zh)
|
2001-01-25 |
2004-04-14 |
����˹�ж�-����˹˹������˾ |
包含埃博霉素类似物的非肠道制剂
|
CZ20032021A3
(cs)
|
2001-01-25 |
2004-05-12 |
Bristol@Myersásquibbácompany |
Způsoby podávání analogů epothilonu při léčbě rakoviny
|
WO2002058699A1
(en)
|
2001-01-25 |
2002-08-01 |
Bristol-Myers Squibb Company |
Pharmaceutical forms of epothilones for oral administration
|
IL156988A0
(en)
|
2001-02-20 |
2004-02-08 |
Bristol Myers Squibb Co |
Pharmaceutical compositions containing epothilone derivatives
|
KR20040028720A
(ko)
|
2001-02-20 |
2004-04-03 |
브리스톨-마이어스스퀴브컴파니 |
치료불응성 종양 치료용 에포틸론 유도체
|
IL157312A0
(en)
*
|
2001-02-27 |
2004-02-19 |
Biotechnolog Forschung Gmbh |
Processes for the preparation of epothilone derivatives and compounds produced thereby
|
US7312237B2
(en)
|
2001-03-14 |
2007-12-25 |
Bristol-Myers Squibb Co. |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
|
WO2002098868A1
(en)
*
|
2001-06-01 |
2002-12-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
CA2456280A1
(en)
*
|
2001-08-23 |
2003-03-06 |
Novartis Ag |
Cyclopropyl and cyclobutyl epothilone analogs
|
WO2003026744A1
(en)
*
|
2001-09-25 |
2003-04-03 |
Alcon, Inc. |
The use of epothilones and analogs in conjunction with ophthalmic surgery
|
IL161462A0
(en)
*
|
2001-10-25 |
2004-09-27 |
Novartis Ag |
Combinations comprising a selective cyclooxygenase-2 inhibitor
|
WO2003048774A1
(en)
*
|
2001-12-07 |
2003-06-12 |
Novartis Ag |
Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
|
EP1469847A1
(en)
|
2002-01-14 |
2004-10-27 |
Novartis AG |
Combinations comprising epothilones and anti-metabolites
|
TW200303202A
(en)
*
|
2002-02-15 |
2003-09-01 |
Bristol Myers Squibb Co |
Method of preparation of 21-amino epothilone derivatives
|
SI1483251T1
(sl)
*
|
2002-03-12 |
2010-03-31 |
Bristol Myers Squibb Co |
C cian epotilonski derivati
|
AU2003218107A1
(en)
|
2002-03-12 |
2003-09-29 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
TW200403994A
(en)
*
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
TW200400191A
(en)
*
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
AU2003243561A1
(en)
|
2002-06-14 |
2003-12-31 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
JP4276171B2
(ja)
*
|
2002-08-02 |
2009-06-10 |
ノバルティス アクチエンゲゼルシャフト |
エポシロン誘導体
|
WO2004018478A2
(en)
*
|
2002-08-23 |
2004-03-04 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6921769B2
(en)
|
2002-08-23 |
2005-07-26 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US7384964B2
(en)
*
|
2002-08-23 |
2008-06-10 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
KR101406635B1
(ko)
|
2002-09-23 |
2014-06-11 |
브리스톨-마이어스 스큅 컴퍼니 |
에포틸론 b의 제조, 분리 및 정제 방법, 및 에포틸론 b의 x-선 결정 구조
|
WO2004035050A1
(en)
*
|
2002-10-15 |
2004-04-29 |
Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College |
Use of epothilone derivatives for the treatment of hyperparathyroidism
|
AU2003302084A1
(en)
|
2002-11-15 |
2004-06-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
EP1559447A1
(en)
|
2004-01-30 |
2005-08-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
GB0405898D0
(en)
*
|
2004-03-16 |
2004-04-21 |
Novartis Ag |
Organic compounds
|
US10675326B2
(en)
|
2004-10-07 |
2020-06-09 |
The Board Of Trustees Of The University Of Illinois |
Compositions comprising cupredoxins for treating cancer
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
JP2008536479A
(ja)
|
2005-02-11 |
2008-09-11 |
ユニバーシティ オブ サザン カリフォルニア |
ジスルフィド架橋を有するタンパク質の発現法
|
CA2607940C
(en)
|
2005-05-18 |
2009-12-15 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
US7893268B2
(en)
*
|
2005-07-27 |
2011-02-22 |
University Of Toledo |
Epithiolone analogues
|
WO2007062288A2
(en)
*
|
2005-11-22 |
2007-05-31 |
The Scripps Research Institute |
Chemical synthesis of a highly potent epothilone
|
US7653731B2
(en)
*
|
2006-02-24 |
2010-01-26 |
Microsoft Corporation |
Management of connections to external data
|
WO2007130501A2
(en)
*
|
2006-05-01 |
2007-11-15 |
University Of Southern California |
Combination therapy for treatment of cancer
|
BRPI0711591A2
(pt)
|
2006-05-16 |
2011-11-16 |
Aegera Therapeutics Inc |
composto de ligação de domìnio bir da iap
|
BRPI0718360A2
(pt)
|
2006-12-04 |
2013-11-12 |
Univ Illinois |
"composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg"
|
EP2114429A4
(en)
|
2007-02-08 |
2010-05-19 |
Univ Illinois |
COMPOSITIONS AND METHODS FOR PREVENTING CANCER WITH CUPREDOXINS
|
WO2008118327A1
(en)
*
|
2007-03-23 |
2008-10-02 |
University Of Toledo |
Conformationally restrained epothilone analogues as anti-leukemic agents
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
DE102007059752A1
(de)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
|
EP2321325A1
(en)
*
|
2008-07-03 |
2011-05-18 |
Pharma Mar S.A. |
Antitumoral macrolides
|
US8802394B2
(en)
|
2008-11-13 |
2014-08-12 |
Radu O. Minea |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
SG182724A1
(en)
|
2010-02-12 |
2012-08-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
CA2799202C
(en)
|
2010-05-18 |
2016-07-05 |
Cerulean Pharma Inc. |
Compositions and methods for treatment of autoimmune and other diseases
|
MX356514B
(es)
|
2011-01-20 |
2018-05-30 |
Univ Texas |
Marcadores de formación de imagen por resonancia magnética, sistemas de suministro y extracción, y métodos de fabricación y uso de los mismos.
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
US9717803B2
(en)
|
2011-12-23 |
2017-08-01 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
US10036010B2
(en)
|
2012-11-09 |
2018-07-31 |
Innate Pharma |
Recognition tags for TGase-mediated conjugation
|
US9725477B2
(en)
|
2012-11-17 |
2017-08-08 |
Beijing Fswelcome Technology Development Co., Ltd |
Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
|
CA2898996A1
(en)
*
|
2013-01-23 |
2014-07-31 |
The University Of Toledo |
Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
|
US10611824B2
(en)
|
2013-03-15 |
2020-04-07 |
Innate Pharma |
Solid phase TGase-mediated conjugation of antibodies
|
US10071169B2
(en)
|
2013-06-20 |
2018-09-11 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
JP6744212B2
(ja)
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
ポリペプチドの酵素的結合
|
WO2017066606A1
(en)
*
|
2015-10-16 |
2017-04-20 |
William Marsh Rice University |
Epothilone analogs, methods of synthesis, methods of treatment, and drug conjugates thereof
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|